jRCT2031260066招募中不适用
A PHASE 3, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER (BEETHOVEN)
未提供0 个研究点目标入组 32,000 人开始时间: 待定
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 32,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
入排标准
- 年龄范围
- 65age old over 至 No limit（—）
- 性别
- All
入选标准
- •Who Can Join the Study (Inclusion Criteria):
- •People with recent or future planned contact with healthcare systems or who have recently received antibiotics.
排除标准
- •Who Cannot Join the Study (Exclusion Criteria):
- •Anyone who has had CDI before.
- •Anyone who has had surgery to remove part of their small or large intestine.
- •Anyone who often has diarrhea (meaning three or more loose stools in a day, more than once a month).
- •Anyone who has already received a vaccine or special antibody treatment for C. difficile.
- •Anyone who has had a serious allergic reaction to a vaccine or to any part of the study vaccines.
- •Anyone who might not respond well to the vaccine because their immune system is weak (either from a disease or from treatment).
- •Anyone with cancer that has spread, kidney failure, or another serious health problem.
研究者
相似试验
尚未招募
不适用
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes (Enith2)OBESITY OR OVERWEIGHT AND TYPE 2 DIABETESjRCT20612500901,600
尚未招募
不适用
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema (A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema)*Atopic Dermatitis
*Eczema, AtopicjRCT2031250615200
招募中
不适用
A PHASE IIb, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION STUDY WITH AN ACTIVE TREATMENT EXTENSION TO ASSESS THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF RO7837195 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITISUlcerative ColitisjRCT204125014317
已完成
1 期
A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MES-1022 IN HEALTHY HUMAN SUBJECTS2023-503866-22-00Mesentech Inc.72
招募中
1 期
A PHASE 1B, MULTICENTER, RANDOMIZED, PLACEBO- CONTROLLED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND BIOLOGICAL ACTIVITY OF TQS-168 IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS2023-504746-54-00Tranquis Therapeutics Inc.16